GoldenGolden
Advanced Search
23andMe

23andMe

A biotechnology company based in Mountain View, California providing DNA genetic testing and analysis services.

23andMe as founded in 2006 by Anne Wojcicki, Linda Avey, Paul Cusenza in 2006. 23andMe provides health and ancestry information based on analysis of a customer’s DNA obtained using a saliva collection kit. Reports are accessed in an online account. Genetic information is kept in separate databases from personally identifiable information to protect user identity.

In 2013 the FDA ordered the company to stop providing information about their customers’ health risks. The FDA later decided to allow 23andMe to tell customers their risks for developing ten medical conditions including Parkinson’s disease, late-onset Alzheimer’s disease and Bloom syndrome.

Each customer can opt in or out for letting 23andMe use their genetic information for research. In 2017 the data from its 2 million customers was considered the largest collection of gene-linked data. 23andMe has its own drug development team lead by Richard Scheller, previously of Genentech who became Chief Science Officer and Head of Therapeutics in 2015. Pharmaceutical company GlaxoSmithKline (GSK) partnered with 23andME in 2018.

Timeline

June 17, 2021
23andMe raises nearly $600 million and went public through a merger with Richard Branson's blank check company.
July 2018
23andMe raises a $300,000,000 corporate funding round from GlaxoSmithKline.
September 2017
23andMe raises a $250,000,000 series F round from Altimeter Capital, Casdin Capital, Euclidean Capital, Fidelity Management & Research Company, Sequoia Capital and the Wallenberg Foundation.
October 2015
23andMe raises a $115,000,000 series E round from Casdin Capital, EquityZen, Illumina Ventures, MPM Capital, New Enterprise Associates, WuXi Healthcare Ventures and xFund.
July 2014
23andMe raises a $1,400,000 grant from National Institutes of Health.
December 10, 2012
23andMe raises a $50,000,000 series D round from Anne Wojcicki, MPM Capital, New Enterprise Associates, Sergey Brin and Yuri Milner.
January 2011
23andMe raises a $9,000,000 series C round from Johnson & Johnson Development Corporation and MPM Capital.
November 9, 2010
23andMe raises a $22,000,000 series C round from New Enterprise Associates.
December 2009
23andMe raises a $14,200,000 series B round.
June 18, 2009
23andMe raises a $12,600,000 series B round from Google and Sergey Brin.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Alex Khomenko

Employee

Anne Wojcicki

Founder

Brad Stephens

Investor

caitlyn mccarthy

Employee

Chia Hwu

Employee

chia@qubop.com

Employee

Chris Cheng

Employee

Denali Lumma

Employee

Dennis Troper

Investor

Desi Dimitrova

Employee

Esther Dyson

Investor

Geoffrey Shmigelsky

Investor

Georges Harik

Investor

J. Fah Sathirapongsasuti

Employee

Jessica Lam

Employee

Jon Ward

Employee

Jonathan Hansen

Employee

Josh Steiner

Employee

Karen Haynes

Employee

Linda Avey

Founder

Martin Varsavsky

Investor

Oliver Ryan

Employee

Patrick S. Chung

Investor

Paul Brobst

Employee

Paul Cusenza

Founder

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.